find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
351
Clinical Trials
CAR-T
Phase I
Enrolling
nct/study# NCT06469281 / 27T51-01
A Phase 1a/1b Study of 27T51, an anti-MUC16 CAR T cell drug product administered alone or in combination for participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer
Learn More
NSCLC
Phase I
Enrolling
nct/study# NCT07140016 / 2215-CL-5201
A Phase 1b Study of Gilteritinib in Participants with Locally Advanced or Metastatic NSCLC with ALK Rearrangement After Prior Treatment with an ALK Inhibitor
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT05327946 / 1501-0001
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab
Learn More
Neuroendocrine
Phase I
Enrolling
nct/study# NCT06132113 / 1438-0007
DAREONTM-7: A Phase I, open-label, dose escalation and expansion trial to investigate safety and tolerability of BI 764532 intravenous infusions in combination with standard of care (platinum and etoposide) in first-line treatment of patients with neuroendocrine carcinomas (NEC)
Learn More
Pediatric Oncology
N/A
Enrolling
nct/study# N/A / TMP
Clinical, Behavioral, and Psychosocial Outcomes of Tumor Molecular Profiling in Children, Adolescents, and Young Adults Treated for Cancer
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT05981703 / BGB-A317-26808-101
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.